NCT00667420终止1 期
A Pilot Study of Perioperative Panitumumab in Combination With Epirubicin, Oxaliplatin and Xeloda in Patients With Resectable Gastroesophageal Adenocarcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Safety and Tolerability
研究概览
简要总结
A pilot study to determine the safety of using perioperative panitumumab with EOX (epirubicin, oxaliplatin, and capecitabine) in patients with adenocarcinoma of the esophagus and stomach.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically or cytologically confirmed diagnosis of adenocarcinoma of the stomach, gastroesophageal junction, or lower third of the esophagus, AJCC stage II-IIIB (gastric) or IIA-IVA (esophageal). M1a disease will be included, but not T4 lesions.
- •No prior radiation or chemotherapy including anti-EGFR or vascular endothelial growth factor (VEGF) antibody or tyrosine kinase inhibitor treatments.
- •All patients must have staging endoscopic ultrasound (EUS) prior to enrollment.
- •Men or Women >18 years of Age
- •ECOG performance status <2 (Karnofsky >60%, see Appendix A).
- •Cardiac ejection fraction >45% by echocardiogram or MUGA scan.
- •Must be able to either swallow pills or have gastrostomy tube in place for administration of enteral medications.
- •Patients must have normal organ, metabolic and marrow function as defined below:
- •Hematologic function, as follows:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- •Platelet count ≥ 100 x 109/L
- •Hemoglobin ≥ 9.0 g/dL
- •Renal function, as follows:
- •Creatinine < or = 1.5 mg/dL x ULN
- •Hepatic function, as follows:
- •Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT)< or = 3 x ULN
- •Total bilirubin < 1.5 x ULN
- •Metabolic function, as follows:
- •Magnesium ≥ lower limit of normal
- •Calcium < or = lower limit of normal -Human IgG is known to cross the placental barrier; therefore, Panitumumab may be transmitted from the mother to the developing fetus. In women of childbearing potential, appropriate contraceptive measures must be used during treatment with panitumumab and for 6 months following the last dose of panitumumab. If panitumumab is used during pregnancy or if the patient becomes pregnant while receiving this drug, she should be apprised of the potential risk for loss of the pregnancy or potential hazard to the fetus.
- •3.1.10 Ability to understand and the willingness to sign and date a written IEC/IRB approved informed consent form.
排除标准
- •Evidence of distant metastatic disease.
- •T4 tumor on initial staging studies.
- •History of another primary cancer, except:
- •Curatively treated in situ cervical cancer
- •Curatively resected non-melanoma skin cancer
- •Other primary solid tumor curatively treated with no known active disease present and no treatment administered for ³ 5 years prior to enrollment
- •Relative or absolute contraindications to surgery which in the opinion of the investigator make the patient a poor candidate for surgical resection.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition to panitumumab or other agents used in study.
- •Subjects requiring chronic use of immunosuppressive agents (e.g., methotrexate, cyclosporine).
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or any evidence of interstitial lung disease on baseline chest CT scan.
- •History of any medical or psychiatric condition or laboratory abnormality that in the opinion of the investigator may increase the risks associated with the study participation or investigational product(s) administration or may interfere with the interpretation of the results.
- •Subject unwilling or unable to comply with study requirements.
- •Women who test positive for serum or urine pregnancy test < 72 hours before randomization or are breast feeding.
- •Known positive test(s) for human immunodeficiency virus infection, hepatitis C virus, acute or chronic active hepatitis B infection.
- •Major surgery with 28 days or minor surgery within 14 days of study enrollment.
- •Men or women of child-bearing potential (women who are post-menopausal < 52 weeks, not surgically sterilized, or not abstinent) not consenting to use adequate contraception (per institutional standard of care) during the course of the study and after the last investigational product(s) administration (24 weeks for women, 4 weeks for men).
- •Subjects with > grade 1 neuropathy at baseline.
- •Contraindication to port-a-cath placement.
研究组 & 干预措施
EOXP chemotherapy
Experimental
open-label, single-arm EOXP Epirubicin 50mg/m2 by IV on day 1 of each 21 day cycle, Oxaliplatin 100 mg/m2 by IV on day 1 of each 21 day cycle, Capecitabine 400 mg/m2 twice daily by mouth on days 1-21 of the 21 day cycle Panitumumab - 9mg/kg by IV on day 1 of each 21 day cycle
干预措施: panitumumab, epirubicin, oxaliplatin, xeloda (Drug)
结局指标
主要结局
Safety and Tolerability
时间窗: after 3 cycles of pre-operative chemotherapy (approx 21 days per cycle)
Safety and tolerability were measured by assessing the number of participants able to complete 3 cycles of pre-operative chemotherapy
次要结局
- R0 Resection Rate(time of surgery = after 3 cycles (approx 63 days) of pre-operative EOX-P chemotherapy)
- Overall Survival(duration from enrollment to death (up to 6 years))
- Progression-Free Survival(up to 72 months)
- Pathologic Complete Response Rate(at surgical resection, after 3 cycles pre-operative chemotherapy (approx 63 days))
研究者
David Patrick Ryan, MD
Clinical Director, MGH Cancer Center
Massachusetts General Hospital
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase II Study of Preoperative Panitumumab and External Beam Radiotherapy in Patients with Locally Advanced Rectal Cancerocally advanced adenocarcinoma of the rectum (T3 - T4 and/or N+ M0), previously untreated and non metastatic diseaseMedDRA version: 9.1Level: LLTClassification code 10038038Term: Rectal cancerEUCTR2009-011325-14-BECliniques Universitaires Saint-Luc42
终止
2 期
Preoperative Panitumumab and Radiotherapy in Rectal CancerRectal CancerNCT00973193Cliniques universitaires Saint-Luc- Université Catholique de Louvain20
终止
2 期
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal AdenocarcinomaGastroesophageal AdenocarcinomaAdenocarcinoma of the Distal EsophagusAdenocarcinomas of the Gastroesophageal JunctionAdenocarcinoma of the Proximal StomachNCT01182610Accelerated Community Oncology Research Network1
Unknown
2 期
Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric CancerPerioperativeSintilimabGastric CancerNCT04982939Tianjin Medical University Cancer Institute and Hospital210
已完成
2 期
Taxol Epirubicin Cyclophosphamide Herceptin Neoadjuvant (TECHNO)Breast CancerNCT00795899German Breast Group230